It has been about a month since the last earnings report for Ironwood Pharmaceuticals (IRWD) . Shares have lost about 18.4% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Ironwood due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Sin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Address of Princ ...

Ironwood Pharmaceuticals (IRWD) reported an adjusted loss of 14 cents per share for the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 5 cents. The company had reported an adjusted loss of 2 cents per share in the year-ago quarter.Total revenues in the first quarter were $41.1 million, which also missed the Zacks Consensus Estimate of $59 million. Revenues decreased around 45.1% year over year. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Sh ...

Ironwood Pharmaceuticals (IRWD) 2025 Conference May 07, 2025 12:00 PM ET Speaker0 Say good afternoon. Welcome to the Citizens Life Science Conference. Happy to be joined next by Ironwood Pharmaceuticals. Ironwood is a company focused on GI diseases and has, been commercializing successfully LINZESS for, about the last decade. Exciting new pipeline product in Aproglutide, for the treatment of short bowel syndrome. We'll we'll we'll talk about that as well. We're we're joined this morning by Tom McCourt, comp ...

Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -180%. A quarter ago, it was expected that this drugmaker would post earnings of $0.10 per share when it actually produced earnings of $0.02, delivering a surprise of -80%.Over the last four quarters, the company ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance – Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in line with full-year expectations - – Raises adjusted EBITDA to greater than $105 million for 2025 – BOSTON, Mass., April 25, 2025 — Ironwood P ...

Ironwood Pharmaceuticals (IRWD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

Shares of Ironwood Pharmaceuticals (IRWD) plunged 31.5% yesterday after it announced regulatory updates on the next-generation GLP-2 analog, apraglutide, which is being developed for treating short bowel syndrome (“SBS”) with intestinal failure (“IF”).Following the recent discussion with the FDA, management noted that a confirmatory phase III study will be required to seek approval of apraglutide for patients with SBS-IF and dependent on parenteral support.Simultaneously, IRWD is looking to explore alternat ...

Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure.Ironwood has engaged Goldman Sachs Group Inc GS to explore strategic alternatives.Apraglutide is a once-weekly, long-acting synthetic GLP-2 analog with the potential to treat rare gastrointestinal diseases.In preparation for the new drug application (NDA) submission, pharmacokinetic analysis indicat ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.I’ve always been intrigued by Ironwood Pharmaceuticals (NASDAQ: IRWD ), dating back about seven years ago when I kept a close eye on the company as I was trying to figure out if Synergy Pharmaceuticals could eventually getHe is the leader of the investin ...